Front. Bioeng. Biotechnol. Frontiers in Bioengineering and Biotechnology Front. Bioeng. Biotechnol. 2296-4185 Frontiers Media S.A. 10.3389/fbioe.2021.656268 Bioengineering and Biotechnology Correction Corrigendum: Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA Zheng Qi Chang 1 † Jiang Shuai 1 † Wu Yu Zhe 1 Shang Dan 2 Zhang Yong 1 Hu Shao Bo 1 Cheng Xiang 1 Zhang Chen 1 Sun Ping 1 Gao Yang 1 Song Zi Fang 1 * Li Min 1 * 1Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 2Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

 *Correspondence: Zi Fang Song zsong@hust.edu.cn Min Li liminmed@hust.edu.cn

This article was submitted to Biomaterials, a section of the journal Frontiers in Bioengineering and Biotechnology

†These authors have contributed equally to this work

 11 02 2021 2021 9 656268 20 01 2021 21 01 2021 Copyright © 2021 Zheng, Jiang, Wu, Shang, Zhang, Hu, Cheng, Zhang, Sun, Gao, Song and Li. 2021 Zheng, Jiang, Wu, Shang, Zhang, Hu, Cheng, Zhang, Sun, Gao, Song and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA by Zheng, Q. C., Jiang, S., Wu, Y. Z., Shang, D., Zhang, Y., Hu, S. B., et al. (2020). Front. Bioeng. Biotechnol. 8:512. doi: 10.3389/fbioe.2020.00512 small interfering RNA gene therapy targeted therapy chitosan hepatocellular carcinoma drug delivery

In the published article, there was an error in affiliations 1 and 2. Affiliation 1 should be “Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China”. Affiliation 2 should be “Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan, China”.

In the original article, there was a mistake in the Graphical Abstract and in Figure 1 as published. “EPR effect” was incorrectly written as “ERP effect”. The corrected Graphical Abstract and Figure 1 appear below.

Schematic representation of GCGA–siPAK1 promoting targeted delivery and therapeutic efficacy in HCC xenograft mouse model. The process includes four steps: (1) intravenous administration of GCGA–siPAK1 via tail vein; (2) NPs accumulation in tumor tissue via passive targeting (commonly known as the EPR effect); (3) three modalities of active targeting via dual-ligand-receptor-mediated endocytosis and mechanism of RNAi (siPAK1-induced PAK1 silencing); (4) tumor biological behaviors after PAK1 silencing; and (5) molecular mechanism of promoting cell apoptosis via PAK1/MEK/ERK pathway.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.